Superworth

RxSight RXST

Medical - Instruments & Supplies, Healthcare
$4.80
−1.44%
Market cap
$199.6M
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
1.6×
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$127.6M
−13% on a year ago
Net margin
−36.8%
Free cash flow yield
−13.6%

RxSight trades at 1.6× sales. Its trailing earnings are negative, so it has no PE. Revenue was $127.6M over the last twelve months, down 13% on a year earlier with a −37% net margin.

Charts

Financials

Income statement for RXST, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$22.2M+76%$28.6M+78%$29.5M+69%$34.9M+68%$35.3M+59%$40.2M+41%$37.9M+28%$33.6M−4%$30.3M−14%$32.6M−19%$30.9M−19%$33.7M+0%
Cost of revenue$8.5M+17%$10.9M+26%$8.8M+24%$10.6M+21%$10.1M+19%$11.4M+5%$9.6M+8%$8.4M−21%$6.1M−39%$7.3M−36%$7.4M−23%n/a
Gross profit$13.7M+156%$17.7M+138%$20.7M+100%$24.3M+102%$25.2M+84%$28.8M+63%$28.3M+37%$25.2M+4%$24.2M−4%$25.3M−12%$23.5M−17%n/a
R&D$7.1M+11%$7.3M+10%$8M+11%$8.3M+12%$8.8M+25%$9.2M+25%$10.4M+29%$10.2M+23%$9.1M+3%$8.9M−3%$9.5M−9%$9.2M−10%
SG&A$19.1M+28%$21.2M+35%$23.3M+44%$24.3M+33%$25.6M+34%$28.2M+33%$28.6M+23%$29M+19%$27.3M+7%$27.7M−2%$31.9M+11%$30.4M+5%
−$12.5M−22%−$10.9M−28%−$10.7M−19%−$8.3M−39%−$9.2M−26%−$8.6M−21%−$10.7M+0%−$14M+68%−$12.2M+32%−$11.3M+31%−$17.8M+67%−$13.8M−2%
Interest expense$230K−82%$4K−100%$6K−100%$6K−100%$5K−98%$5K+25%$6K+0%$5K−17%$4K−20%$5K+0%$3K−50%$3K−40%
Pre-tax income−$12.4M−26%−$9.2M−41%−$9.1M−31%−$6.1M−56%−$6.3M−49%−$5.9M−36%−$8.2M−10%−$11.8M+94%−$9.8M+55%−$9.1M+54%−$15.9M+94%−$12M+2%
$12K−$18K$9K$16K−39%$13K+8%$12K$18K+100%$32K+100%$10K−23%$5K−58%$6K−67%$88K+175%
Net income−$12.4M−26%−$9.2M−41%−$9.1M−31%−$6.1M−56%−$6.3M−49%−$5.9M−35%−$8.2M−10%−$11.8M+94%−$9.8M+55%−$9.2M+54%−$15.9M+94%−$12.1M+3%
−$0.35−43%−$0.26−54%−$0.25−41%−$0.16−60%−$0.16−54%−$0.15−42%−$0.20−20%−$0.29+81%−$0.24+50%−$0.22+47%−$0.38+90%−$0.29+0%
35.7M+29%36M+29%36.8M+17%38.5M+12%39.8M+12%40.4M+12%40.5M+10%40.7M+6%41M+3%41.2M+2%41.3M+2%41.5M+2%

Revenue: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.

Cost of revenue: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.

Gross profit: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.

R&D: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.

SG&A: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.

Operating income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.

Interest expense: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.

Pre-tax income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.

Income tax: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.

Net income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.

EPS, diluted: 5 periods, Q4 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 5 periods, Q4 FY21 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Medical - Instruments & Supplies nearest RxSight's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
RXSTRxSight$199.6Mn/mn/a1.6×−13%−36.8%
PDEXPro DEX$184.5M15.9×16.5×2.3×+13%15.1%
UTMDUtah Medical Products$224.6M21.5×20.9×6.2×−7%29.0%
INFUInfuSystem$275.7M33.8×43.5×1.9×+2%6.0%
EMBCEmbecta$350.7M4.2×11.6×0.3×−8%8.6%
KEQUKewaunee Scientific$96.7M12.1×13.6×0.3×+5%3.0%
TCMDTactile Systems Technology$518.1M21.2×62.3×1.5×+17%7.1%
APTAlpha Pro Tech$56.3M13.5×14.8×0.9×+6%6.8%
MOVMovado$710.9M17.7×13.4×1.0×+5%6.0%
IRMDIradimed$1B42.5×41.5×11.4×+11%26.8%
IARTIntegra Lifesciences$1.1B80.1×46.3×0.6×+1%0.8%
Peer median$313.2M19.4×18.7×1.3×+5%6.9%

More on RxSight

Each number over time

Its groups

About

Industry
Medical - Instruments & Supplies
Sector
Healthcare

Valuation data, not investment advice. Prices as of .